Loading
OI
Omnicell, Inc. Stock: price and insider trades · United States
US·Mcap US$1.6B
No insider purchase over the last 90 days. The latest was filed 18 Mar 2025.
Omnicell, Inc.: what insiders have been doing
This page follows insider dealings at Omnicell, Inc. as filed with SEC (Form 4). Over the twelve months to 18 October 2026, 33 filings were filed, from 10 insiders.
There is no open-market purchase to report; the filings show 3 sales worth €881k by 2 insiders. The largest single trade was a sale of €411k by Lipps Randall A, published on 17 July 2026, equal to 0.029% of the market capitalisation.
With 33 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2016, counts 3 purchases against 15 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.18 bn USD and net income of 2.1 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
249
Thresholds
n/a
Buy Volume
€600,846
3 ops. · all time
Sell Volume
€3M
15 ops. · all time
Who traded when
BuySaleCorey J. Manley3 sales
Randall A. Lipps1 buy1 sale
Parrish Mark W1 sale
Since the insiders bought
- +180.8%Entry US$9.78 · Close at T+365 US$27.46
- -17.5%Entry US$139.83 · Close at T+365 US$115.41
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Omnicell, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$57.86.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,089 of 24,148 companies
40.7
score / 100
Value39
Quality43
FCF yld4.3%
Earn yld0.1%
EV/EBITDA19.8x
ROE3.1%
Gross mgn42%
Net mgn0.2%
Debt/EBITDA2.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$35.39
Analyst consensus
7 analystsStrong buy
US$45.00Target US$57.86(+63%)US$70.00
Income statement
RevenueUS$1.2B
Gross profitUS$503.4M42% margin
EBITDAUS$91.8M8% margin
Net incomeUS$2.1M3.1% margin
Valuation
PER (trailing)42.1x
PER (forward)17.2x
P/Book1.2x
Beta0.99
Balance sheet & cash
Market capUS$1.6B
Total debtUS$204.3M
Free Cash FlowUS$69.4M
Debt / Equity15%
Profitability & ownership
ROE3.1%
ROA1.5%
% insiders2.1%
% institutions109.1%
Last declaration on 18 August 2026
Declarations249 total
3,670 shares@ US$37.300.0083% mcap31.6% of flowCommon StockSEC:0002034946-26-000013:0
12,350 shares@ US$37.300.028% mcap8.3% of flowCommon StockSEC:0001227556-26-000012:0
4,025 shares@ US$37.300.0091% mcap10.4% of flowCommon StockSEC:0001928727-26-000012:0
937 shares@ US$37.300.0021% mcap47.2% of flowCommon StockSEC:0001520961-26-000008:0
3,083 shares@ US$36.850.0069% mcap26.1% of flowCommonSEC144:0001959173-26-006055
10,000 shares@ US$47.000.029% mcap8.5% of flowCommon StockSEC:0001227556-26-000010:0
10,000 shares@ US$47.000.031% mcap100.0% of flowCommonSEC144:0001628280-26-048331
12,309 shares0Common StockSEC:0002034946-26-000011:0
5,027 shares0Common StockSEC:0001359343-26-000002:0
4,603 shares0Common StockSEC:0001452605-26-000002:0
25,132 shares0Common StockSEC:0001928727-26-000008:0
46,296 shares0Common StockSEC:0002034946-26-000006:0
90,939 shares0Common StockSEC:0001227556-26-000006:0
5,556 shares0Common StockSEC:0001520961-26-000004:0
37,037 shares0Common StockSEC:0001398311-26-000002:0
37,409 shares0Common StockSEC:0002034946-26-000004:0
22,445 shares0Common StockSEC:0001928727-26-000006:0
79,494 shares0Common StockSEC:0001227556-26-000004:0
5,294 shares@ US$36.503.4% of flowCommon StockSEC:0001227556-26-000002:0
1,146 shares@ US$36.509.4% of flowCommon StockSEC:0002034946-26-000002:0
2,022 shares@ US$36.505.0% of flowCommon StockSEC:0001928727-26-000004:0
258 shares@ US$36.5012.4% of flowCommon StockSEC:0001520961-26-000002:0
6,106 shares@ US$49.9020.8% of flowCommon StockSEC:0001928727-26-000002:0
1,147 shares@ US$43.270.9% of flowCommon StockSEC:0001227556-25-000009:0
224 shares@ US$43.270.7% of flowCommon StockSEC:0001928727-25-000010:0
25 of 249 declarations
About Omnicell, Inc.
Omnicell, Inc. is a company specializing in medication and healthcare management solutions. It offers innovative technologies to enhance the efficiency of pharmacies and healthcare facilities.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
